Monocrotaline

MCE 國際站：Monocrotaline

品牌：MedChemExpress (MCE)

貨號：HY-N0750

CAS：315-22-0

中文名稱：野百合堿；單響尾蛇毒蛋白；大葉豬尿青堿；農吉利甲素；農吉利堿；豬屎豆堿

Synonyms：野百合堿; Crotaline

純度：99.98%

存儲條件：4°C，密封保存，避光防潮 *溶劑中：-80°C，6個月；-20°C，1個月（密封保存，避光防潮）

運輸條件：美國大陸的室溫；其他地方可能有所不同。

產品活性：Monocrotaline 是一種 11 元大環吡咯利西啶生物堿。Monocrotaline 對 OCT-1 和 OCT-2 有抑制作用，其 IC50 值分別為 36.8 µM 和 1.8 mM。Monocrotaline 具有抗腫瘤活性，對肝癌細胞有一定的細胞毒性。Monocrotaline 用于在嚙齒動物中誘導肺動脈高壓模型[2][6][8]。

生物活性：Monocrotaline 是一種吡咯里西啶生物堿，從 Crotalaria pallida 植物的種子中提取，可誘導嚙齒動物肺動脈高壓。 

體外：野百合堿 (Monocrotaline) 是一種具有劑量依賴性細胞毒性的天然配體，具有抗腫瘤活性。Monocrotaline 對 HepG2 細胞 [2] 的體外細胞毒性為 IC50 為 24.966 µg/mL和遺傳毒性為 2 x IC50。 MCE尚未獨立證實這些方法的準確性。僅供參考。

IC50 & Target：OCT1 36.8 μM (IC50) OCT2 1852.6 μM (IC50)

熱銷產品：TAMRA azide, 5-isomer  | 7α-Hydroxy-4-cholesten-3-one  | Chlorin e6  | MAK683  | Eprenetapopt  | AZD1080  | Nimotuzumab  | Progesterone  | Osimertinib (mesylate)  (ammonium)

Trending products：Recombinant Proteins  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Oligonucleotides

參考文獻：

[1]. Gomez-Arroyo JG, et al. The monocrotaline model of pulmonary hypertension in perspective. Am J Physiol Lung Cell Mol Physiol. 2012 Feb 15;302(4):L363-9.
[2]. Wu XH, et al. Experimental animal models of pulmonary hypertension: Development and challenges. Animal Model Exp Med. 2022 Sep; 5(3):207-216.
[3]. Kusuma SS, et al. Antineoplastic activity of monocrotaline against hepatocellular carcinoma. Anticancer Agents Med Chem. 2014;14(9):1237-48.
[4]. Jin H, et al. Astragaloside IV blocks monocrotaline?induced pulmonary arterial hypertension by improving inflammation and pulmonary artery remodeling. Int J Mol Med. 2021 Feb;47(2):595-606.
[5]. Wilson DW, et, al. Mechanisms and pathology of monocrotaline pulmonary toxicity. Crit Rev Toxicol. 1992;22(5-6):307-25.
[6]. Chen JY, et al. An in vitro study on interaction of anisodine and monocrotaline with organic cation transporters of the SLC22 and SLC47 families. Chin J Nat Med. 2019 Jul;17(7):490-497.
[7]. Nogueira-Ferreira R, et al. Exploring the monocrotaline animal model for the study of pulmonary arterial hypertension: A network approach. Pulm Pharmacol Ther. 2015 Dec;35:8-16.
[8]. Zhao J, et al. Effects of paclitaxel intervention on pulmonary vascular remodeling in rats with pulmonary hypertension. Exp Ther Med. 2019 Feb;17(2):1163-1170.
[9]. Rafikova O,et al. Metabolic Changes Precede the Development of Pulmonary Hypertension in the Monocrotaline Exposed RatLung. PLoS One. 2016 Mar 3;11(3):e0150480.
[10]. Dumitrascu R, Kulcke C, K?nigshoff M, Kouri F, Yang X, Morrell N, Ghofrani HA, Weissmann N, Reiter R, Seeger W, Grimminger F, Eickelberg O, Schermuly RT, Pullamsetti SS. Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats. Eur Respir J. 2011 May;37(5):1104-18.
[11]. Aliotta JM, Pereira M, Wen S, Dooner MS, Del Tatto M, Papa E, Goldberg LR, Baird GL, Ventetuolo CE, Quesenberry PJ, Klinger JR. Exosomes induce and reverse monocrotaline-induced pulmonary hypertension in mice. Cardiovasc Res. 2016 Jun 1;110(3):319-30.